Cargando…
Comparison of treatment plans for hypofractionated high‐dose prostate cancer radiotherapy using the Varian Halcyon and the Elekta Synergy platforms
PURPOSE: To compare radiotherapy plans between an O‐ring and a conventional C‐arm linac for hypofractionated high‐dose prostate radiotherapy in terms of plan quality, dose distribution, and quality assurance in a multi‐vendor environment. METHODS: Twenty prostate cancer treatment plans were irradiat...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8425948/ https://www.ncbi.nlm.nih.gov/pubmed/34351055 http://dx.doi.org/10.1002/acm2.13380 |
_version_ | 1783749946384580608 |
---|---|
author | Tamihardja, Jörg Razinskas, Gary Exner, Florian Richter, Anne Kessler, Patrick Weick, Stefan Kraft, Johannes Mantel, Frederick Flentje, Michael Polat, Bülent |
author_facet | Tamihardja, Jörg Razinskas, Gary Exner, Florian Richter, Anne Kessler, Patrick Weick, Stefan Kraft, Johannes Mantel, Frederick Flentje, Michael Polat, Bülent |
author_sort | Tamihardja, Jörg |
collection | PubMed |
description | PURPOSE: To compare radiotherapy plans between an O‐ring and a conventional C‐arm linac for hypofractionated high‐dose prostate radiotherapy in terms of plan quality, dose distribution, and quality assurance in a multi‐vendor environment. METHODS: Twenty prostate cancer treatment plans were irradiated on the O‐ring Varian Halcyon linac and were re‐optimized for the C‐arm Elekta Synergy Agility linac. Dose‐volume histogram metrics for target coverage and organ at risk dose, quality assurance, and monitor units were retrospectively compared. Patient‐specific quality assurance with ion chamber measurements, gamma index analysis, and portal dosimetry was performed using the Varian Portal Dosimetry system and the ArcCHECK(®) phantom (Sun Nuclear Corporation). Prostate‐only radiotherapy was delivered with simultaneous integrated boost (SIB) volumetric modulated arc therapy (VMAT) in 20 fractions of 2.5/3.0 Gy each. RESULTS: For both linacs, target coverage was excellent and plan quality comparable. Homogeneity in PTV(Boost) was high for Synergy as well as Halcyon with a mean homogeneity index of 0.07 ± 0.01 and 0.05 ± 0.01, respectively. Mean dose for the organs at risk rectum and bladder differed not significantly between the linacs but were higher for the femoral heads and penile bulb for Halcyon. Quality assurance showed no significant differences in terms of ArcCHECK gamma pass rates. Median pass rate for 3%/2 mm was 99.3% (96.7 to 99.8%) for Synergy and 99.8% (95.6 to 100%) for Halcyon. Agreement between calculated and measured dose was high with a median deviation of −0.6% (−1.7 to 0.8%) for Synergy and 0.2% (−0.6 to 2.3%) for Halcyon. Monitor units were higher for the Halcyon by approximately 20% (p < 0.001). CONCLUSION: Hypofractionated high‐dose prostate cancer SIB VMAT on the Halcyon system is feasible with comparable plan quality in reference to a standard C‐arm Elekta Synergy linac. |
format | Online Article Text |
id | pubmed-8425948 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-84259482021-09-13 Comparison of treatment plans for hypofractionated high‐dose prostate cancer radiotherapy using the Varian Halcyon and the Elekta Synergy platforms Tamihardja, Jörg Razinskas, Gary Exner, Florian Richter, Anne Kessler, Patrick Weick, Stefan Kraft, Johannes Mantel, Frederick Flentje, Michael Polat, Bülent J Appl Clin Med Phys Radiation Oncology Physics PURPOSE: To compare radiotherapy plans between an O‐ring and a conventional C‐arm linac for hypofractionated high‐dose prostate radiotherapy in terms of plan quality, dose distribution, and quality assurance in a multi‐vendor environment. METHODS: Twenty prostate cancer treatment plans were irradiated on the O‐ring Varian Halcyon linac and were re‐optimized for the C‐arm Elekta Synergy Agility linac. Dose‐volume histogram metrics for target coverage and organ at risk dose, quality assurance, and monitor units were retrospectively compared. Patient‐specific quality assurance with ion chamber measurements, gamma index analysis, and portal dosimetry was performed using the Varian Portal Dosimetry system and the ArcCHECK(®) phantom (Sun Nuclear Corporation). Prostate‐only radiotherapy was delivered with simultaneous integrated boost (SIB) volumetric modulated arc therapy (VMAT) in 20 fractions of 2.5/3.0 Gy each. RESULTS: For both linacs, target coverage was excellent and plan quality comparable. Homogeneity in PTV(Boost) was high for Synergy as well as Halcyon with a mean homogeneity index of 0.07 ± 0.01 and 0.05 ± 0.01, respectively. Mean dose for the organs at risk rectum and bladder differed not significantly between the linacs but were higher for the femoral heads and penile bulb for Halcyon. Quality assurance showed no significant differences in terms of ArcCHECK gamma pass rates. Median pass rate for 3%/2 mm was 99.3% (96.7 to 99.8%) for Synergy and 99.8% (95.6 to 100%) for Halcyon. Agreement between calculated and measured dose was high with a median deviation of −0.6% (−1.7 to 0.8%) for Synergy and 0.2% (−0.6 to 2.3%) for Halcyon. Monitor units were higher for the Halcyon by approximately 20% (p < 0.001). CONCLUSION: Hypofractionated high‐dose prostate cancer SIB VMAT on the Halcyon system is feasible with comparable plan quality in reference to a standard C‐arm Elekta Synergy linac. John Wiley and Sons Inc. 2021-08-05 /pmc/articles/PMC8425948/ /pubmed/34351055 http://dx.doi.org/10.1002/acm2.13380 Text en © 2021 The Authors. Journal of Applied Clinical Medical Physics published by Wiley Periodicals LLC on behalf of American Association of Physicists in Medicine https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Radiation Oncology Physics Tamihardja, Jörg Razinskas, Gary Exner, Florian Richter, Anne Kessler, Patrick Weick, Stefan Kraft, Johannes Mantel, Frederick Flentje, Michael Polat, Bülent Comparison of treatment plans for hypofractionated high‐dose prostate cancer radiotherapy using the Varian Halcyon and the Elekta Synergy platforms |
title | Comparison of treatment plans for hypofractionated high‐dose prostate cancer radiotherapy using the Varian Halcyon and the Elekta Synergy platforms |
title_full | Comparison of treatment plans for hypofractionated high‐dose prostate cancer radiotherapy using the Varian Halcyon and the Elekta Synergy platforms |
title_fullStr | Comparison of treatment plans for hypofractionated high‐dose prostate cancer radiotherapy using the Varian Halcyon and the Elekta Synergy platforms |
title_full_unstemmed | Comparison of treatment plans for hypofractionated high‐dose prostate cancer radiotherapy using the Varian Halcyon and the Elekta Synergy platforms |
title_short | Comparison of treatment plans for hypofractionated high‐dose prostate cancer radiotherapy using the Varian Halcyon and the Elekta Synergy platforms |
title_sort | comparison of treatment plans for hypofractionated high‐dose prostate cancer radiotherapy using the varian halcyon and the elekta synergy platforms |
topic | Radiation Oncology Physics |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8425948/ https://www.ncbi.nlm.nih.gov/pubmed/34351055 http://dx.doi.org/10.1002/acm2.13380 |
work_keys_str_mv | AT tamihardjajorg comparisonoftreatmentplansforhypofractionatedhighdoseprostatecancerradiotherapyusingthevarianhalcyonandtheelektasynergyplatforms AT razinskasgary comparisonoftreatmentplansforhypofractionatedhighdoseprostatecancerradiotherapyusingthevarianhalcyonandtheelektasynergyplatforms AT exnerflorian comparisonoftreatmentplansforhypofractionatedhighdoseprostatecancerradiotherapyusingthevarianhalcyonandtheelektasynergyplatforms AT richteranne comparisonoftreatmentplansforhypofractionatedhighdoseprostatecancerradiotherapyusingthevarianhalcyonandtheelektasynergyplatforms AT kesslerpatrick comparisonoftreatmentplansforhypofractionatedhighdoseprostatecancerradiotherapyusingthevarianhalcyonandtheelektasynergyplatforms AT weickstefan comparisonoftreatmentplansforhypofractionatedhighdoseprostatecancerradiotherapyusingthevarianhalcyonandtheelektasynergyplatforms AT kraftjohannes comparisonoftreatmentplansforhypofractionatedhighdoseprostatecancerradiotherapyusingthevarianhalcyonandtheelektasynergyplatforms AT mantelfrederick comparisonoftreatmentplansforhypofractionatedhighdoseprostatecancerradiotherapyusingthevarianhalcyonandtheelektasynergyplatforms AT flentjemichael comparisonoftreatmentplansforhypofractionatedhighdoseprostatecancerradiotherapyusingthevarianhalcyonandtheelektasynergyplatforms AT polatbulent comparisonoftreatmentplansforhypofractionatedhighdoseprostatecancerradiotherapyusingthevarianhalcyonandtheelektasynergyplatforms |